Purinergic signaling during intestinal inflammation

Area of Science:

• Immunology
• Gastroenterology
• Pharmacology

Background:

• Inflammatory bowel disease (IBD) is characterized by excessive intestinal inflammation in susceptible individuals, often triggered by microbial imbalances.
• IBD increases risks for thrombophilia, chronic debility, and cancers of the bowel, lymphatic system, and liver.
• Current therapies aim to re-establish immune tolerance without raising infection or cancer risks.

Purpose of the Study:

• To review novel functions of CD39 and related ectonucleotidases (NTPDases) in the context of IBD pathogenesis.
• To explore the role of purinergic signaling in immune and thrombotic dysregulation observed in IBD.
• To investigate the connection between the aryl hydrocarbon receptor (AHR) and CD39 expression in IBD.

Main Methods:

• Review of existing literature on CD39, NTPDases, purinergic signaling, and IBD.
• Analysis of the interplay between CD39, immune cells (dendritic cells, myeloid cells, T cells, B cells), and endothelial cells.
• Examination of the regulatory mechanisms of CD39 expression and activity, including AHR ligation.

Main Results:

• Aberrant purinergic signaling contributes to thrombophilia, inflammation, and immune disturbances in IBD.
• CD39 expression integrates hemostasis and immunity, with its dysregulation implicated in IBD.
• Aryl hydrocarbon receptor (AHR) ligation upregulates CD39, while decreased CD39 or dysfunctional AHR signaling diminishes protective effects.

Conclusions:

• CD39 plays a critical role in immune and hemostatic balance, which is disrupted in IBD.
• Dysfunctional purinergic signaling, involving CD39, is a key feature of IBD.
• Therapeutic strategies targeting CD39 ectonucleotidase activity, potentially via AHR ligands, show promise for managing IBD complications.